Hofmann H
Klinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Germany.
Infection. 1996 Nov-Dec;24(6):470-2. doi: 10.1007/BF01713052.
As long as test procedures are not standardized, the serological results of IgM- and IgG-antibodies in Lyme borreliosis must be interpreted with caution and always in the context of clinical signs and symptoms. False negative results occur primarily during the first weeks of infection. In erythema migrans of less than 4 weeks' duration, 50% of patients are seronegative even with newly designed ELISAs. At this early stage of the infection the therapeutic decision has to be established on the basis of clinical criteria. Frequently IgM- and/or IgG-antibodies develop during antibiotic therapy. After 4 weeks' duration 80% of patients have elevated borrelial antibodies detectable with recently developed ELISAs. Positive and borderline results should be confirmed by Western blot. False positive results, particularly slightly elevated IgM, may occur in a variety of other diseases. Another problem is the persistence of Borrelia-specific IgM antibodies after therapy. Serological follow-up can only be carried out with the same methods in the same laboratory. Retreatment should be considered if IgM antibodies are increasing significantly and new symptoms are occurring.
只要检测程序不规范,莱姆病中IgM和IgG抗体的血清学结果就必须谨慎解读,并且始终要结合临床体征和症状来判断。假阴性结果主要出现在感染后的最初几周。在病程小于4周的游走性红斑患者中,即使采用新设计的酶联免疫吸附测定(ELISA),仍有50%的患者血清学检测呈阴性。在感染的这个早期阶段,治疗决策必须基于临床标准来制定。在抗生素治疗期间,IgM和/或IgG抗体常常会出现。病程4周后,80%的患者通过最近开发的ELISA可检测到伯氏疏螺旋体抗体升高。阳性和临界结果应由免疫印迹法确认。假阳性结果,尤其是IgM轻度升高,可能出现在多种其他疾病中。另一个问题是治疗后伯氏疏螺旋体特异性IgM抗体持续存在。血清学随访只能在同一实验室采用相同方法进行。如果IgM抗体显著升高且出现新症状,则应考虑再次治疗。